| Literature DB >> 34959440 |
Danyingzi Guan1, Bianfei Xuan2, Chengguang Wang3, Ruitao Long1, Yaqin Jiang1, Lina Mao1, Jinbing Kang1, Ziwen Wang1, Shing Fung Chow2, Qun Zhou1.
Abstract
Active pharmaceutical ingredients (APIs) extracted and isolated from traditional Chinese medicines (TCMs) are of interest for drug development due to their wide range of biological activities. However, the overwhelming majority of APIs in TCMs (T-APIs), including flavonoids, terpenoids, alkaloids and phenolic acids, are limited by their poor physicochemical and biopharmaceutical properties, such as solubility, dissolution performance, stability and tabletability for drug development. Cocrystallization of these T-APIs with coformers offers unique advantages to modulate physicochemical properties of these drugs without compromising the therapeutic benefits by non-covalent interactions. This review provides a comprehensive overview of current challenges, applications, and future directions of T-API cocrystals, including cocrystal designs, preparation methods, modifications and corresponding mechanisms of physicochemical and biopharmaceutical properties. Moreover, a variety of studies are presented to elucidate the relationship between the crystal structures of cocrystals and their resulting properties, along with the underlying mechanism for such changes. It is believed that a comprehensive understanding of cocrystal engineering could contribute to the development of more bioactive natural compounds into new drugs.Entities:
Keywords: active pharmaceutical ingredients; cocrystal engineering; dissolution; pharmaceutical cocrystal; physicochemical properties; solubility; stability; traditional Chinese medicine
Year: 2021 PMID: 34959440 PMCID: PMC8704577 DOI: 10.3390/pharmaceutics13122160
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
The problematic physiochemical properties of some T-APIs as new potential drugs [9].
| Name of T-APIs | Main Sources of Plants | Problematic Physicochemical Properties | Major Indications |
|---|---|---|---|
|
| |||
|
| Slightly soluble | Tachyarrhythmia | |
|
| Practically insoluble | Intestinal and external amoeba | |
|
| - | Chronic cervicitis, dysentery, enteritis, skin disease | |
|
| Slightly soluble | Cancer, chronic bronchial asthma, malignant mole | |
|
| Slightly soluble | Rheumatic pain | |
|
| |||
|
| Practically insoluble | HIV and other viral infections, inflammation | |
|
| Practically insoluble, unstable, prone to oxidation | Fever, sore throat, and upper respiratory tract infection | |
|
| Practically insoluble | Cardiovascular and cerebrovascular diseases, inflammation | |
|
| Hygroscopic, prone to oxidation and decomposition | Alcoholism, alcoholic liver, fatty liver | |
|
| Practically insoluble | Cancer | |
|
| Practically insoluble | Various diseases related to venous and lymphatic insufficiency, hypertension, and myocardial infarction | |
|
| Slightly soluble | Osteoclast bone resorption | |
|
| Slightly soluble, low bioavailability | Cardiovascular disease, amyotrophic lateral sclerosis | |
|
| Myricaceae, Vitaceae, Leguminosae, Ericaceae, and Euphorbiaceae. | Slightly soluble, low bioavailability | Cardiovascular disease |
|
| Practically insoluble, low bioavailability | Bacterial infection, cough, cancer | |
|
| Practically insoluble, low bioavailability | Bacterial infection, viral infection, tumor, diabetes, hyperlipidemia, and immune system diseases | |
|
| |||
|
| Practically insoluble, poor stability, prone to degradation, poor solubility in acidic condition, low dissolution rate and bioavailability | Inflammatory bowel disease, pancreatitis, arthritis | |
|
| Practically insoluble | Cardiovascular diseases, cerebrovascular diseases, leukopenia, and other diseases | |
|
| Slightly soluble | High blood pressure, hyperlipidemia, colon cancer, skin tumors | |
|
| Practically insoluble | Bronchitis, pneumonia, acute tonsillitis, periodontitis, bacillary dysentery, acute gastroenteritis, urinary infection, acute hepatitis | |
|
| Practically insoluble | High blood pressure, hyperlipidemia, colon cancer, skin tumors | |
|
| Practically insoluble, photosensitive, thermally unstable | Cancer, high blood cholesterol | |
|
| Rheum officinale Baill. | Practically insoluble | Hyperlipidemia, constipation |
|
| Practically insoluble | Viral hepatitis, depression, primary hyperlipidemia | |
|
| Photosensitive, thermally unstable, prone to degradation | Ischemic stroke | |
|
| |||
|
| Practically insoluble | Cancer | |
|
| Practically insoluble | Rheumatoid arthritis |
Notes: According to the British Pharmacopoeia, <0.1 mg/mL refers to practically insoluble, 1–10 mg/mL refers to slightly soluble, both of which will lead to low bioavailability.
Figure 1Different solid-state forms of an API.
Sources of plants, physicochemical problems, and major indications of T-APIs, including alkaloids, flavonoids, phenolic acids and terpenoids, recorded in Volume II, Chinese Pharmacopoeia (2020 edition) [36].
| Name of T-APIs | Main Sources of Plants | Problematic Physicochemical Properties | Major Indications |
|---|---|---|---|
|
| |||
|
| Slightly soluble, low bioavailability, bitter taste | Diabetes, high blood pressure | |
|
| The subgenus Subgen. Aconitum. | Practically insoluble | Rheumatoid arthritis |
|
| The genus Cephalotaxus. | Slightly soluble | Acute myelogenous |
|
| The genus Huperzia, i.e., | Practically insoluble, hygroscopic | Senile dementia, |
|
| - | Nasal congestion caused | |
|
| - | Choline drug resistance, | |
|
| The genus Rauvolfia. | Slightly soluble, photosensitive | Mild and moderate |
|
| Slightly soluble, prone to oxidation, photosensitive | medical ailments, prenatal | |
|
| Prone to sublimation, hygroscopic | Vasodilator, occlusive cerebrovascul- | |
|
| Hygroscopic, photosensitive, prone to thermal degradation | Hodgkin’s disease, | |
|
| Hygroscopic, photosensitive, prone to thermal degradation | Acute leukemia | |
|
| |||
|
| Slightly soluble, low bioavailability, poor tabletability | Acute and chronic hepatitis, | |
|
| Practically insoluble, hygroscopic | Hypertensive encephalopathy, | |
|
| |||
|
| - | Practically insoluble | Cholecystitis, cholelithiasis, |
|
| Slightly soluble | Cerebral thrombosis, | |
|
| |||
|
| Practically insoluble | Upper respiratory tract infection, | |
|
| Practically insoluble | Plasmodium falciparum, dangerous malaria resistant to chloroquine | |
|
| Practically insoluble, low bioavailability, short biological half-life, frequent drug administration is needed | Malaria, pulmonary hypertension | |
|
| Slightly soluble | Cerebral malaria and various critical malaria | |
|
| - | Slightly soluble | Malaria |
|
| Low aqueous soluable, volatile | Skin irritant | |
|
| Some various plants of the genus Taxus Linn. | Practically insoluble | Ovarian cancer, |
Notes: According to the British Pharmacopoeia, <0.1 mg/mL refers to practically insoluble, 1–10 mg/mL refers to slightly soluble, both of which will lead to low bioavailability.
Figure 2The representative compounds of flavonoids, alkaloids, phenolic acids and terpenoids in this review.
Supramolecular interactions formed in the reported T-APIs.
| Drug | Coformer | Single Crystal Structure | Supramolecular Interactions |
|---|---|---|---|
|
| |||
|
| Citric acid [ | Reported | −COOH···Cl |
|
| Phthalic acid * [ | - | - |
|
| Bexarotene [ | Reported | O−H···N |
|
| |||
|
| 4,4′-Bipyridine * [ | Reported | O−H···N, |
|
| Nicotinamide [ | Reported | O−H···N, |
|
| Cytosine [ | Reported | N−H···N |
|
| Pentoxifylline [ | Reported | O−H···O |
|
| Nicotinamide [ | Reported | O−H···Narom |
|
| Isonicotinamide [ | Reported | O−H···N |
|
| Caffeine [ | Reported | O−H···N |
|
| 5-Fluorouracil [ | Reported | O−H···N, |
|
| Isonicotinamide [ | Reported | O−H···Narom |
|
| 4,4′-Bipyridine * [ | Reported | O−H···N, |
|
| 4-Hydroxypyridine [ | Reported | O−H···C=O |
|
| Lornoxicam [ | - | - |
|
| 4,4′-Bipyridine * [ | Reported | O−H···N, |
|
| |||
|
| Isoniazid [ | - | - |
|
| Metronidazole [ | Reported | O−H···O |
|
| Pyrazinamide [ | Reported | C=O···N−H |
|
| Isoniazid [ | - | - |
|
| Ethylenediamine * [ | Reported | C−H···π |
|
| Curcumin [ | - | - |
|
| Ethylenediamine * [ | - | - |
|
| |||
|
| Salicylic acid [ | Reported | O−H···O, |
|
| Orcinol [ | Reported | C−H···O, |
|
| Nicotinamide [ | - | - |
|
| Benzoic acid [ | - | - |
Note: * indicates belonging to non-GARS or non-drug compounds.
Figure 3Typical hydrogen bounded elements in pharmaceutical cocrystals observed in (a) flavonoids, (b) alkaloids, (c) phenolic acids and (d) terpenoids.
Figure 4(a) Two-dimensional network formed between chloride anion and myricetin moieties via O–H⋯O and O–H⋯Cl– interactions viewed along the a-axis (capped stick model). (b) Two-dimensional network formed between chloride anion and dihydromyricetin moieties via O–H⋯O and O–H⋯Cl– interactions viewed along the a-axis (capped stick model) [64] (with permission from [64]; Copyright 2019 American Chemical Society).
Figure 5(a) ORTEP plot of berberine–chrysin cocrystal with 35% probability level. H atoms on C were omitted for clarity. Dashed lines represent hydrogen-bonding interactions. (b) Supramolecular structure resulting from C–H⋯O and π–π interactions [66] (adapted with permission from [66]; Copyright 2018 American Chemical Society).
Figure 6Crystal structures of TMP-SAC (a–c) and TMP-ACS (d–f). The blue lines represent hydrogen bonds [31] (with permission from [31]; Copyright 2020 American Chemical Society).
The preparation methods of T-API cocrystals.
| Preparation Methods | Drug | Co-Former |
|---|---|---|
| Slow evaporation | Baicalein | Caffeine [ |
| Berberine | Phthalic acid * [ | |
| Curcumin | 2-Aminopyridine * [ | |
| Rutin | Carbamide [ | |
| Puerarin | Lornoxicam [ | |
| Ferulic acid | Nicotinamide [ | |
| Ursolic acid | Ethylenediamine * [ | |
| Oleanolic acid | Ethylenediamine * [ | |
| Ligustrazine | Saccharine [ | |
| Rapid solvent removal | Curcumin | Isoniazid [ |
| Slurry | Berberine chloride | Fumaric acid [ |
| Recrystallization | Matrine | Salvianolic acid B [ |
| Supercritical fluids | Resveratrol | Curcumin [ |
| Antisolvent precipitation | Ursolic acid | Metformin [ |
| Neat grinding | Curcumin | Trimesic acid [ |
| Solvent assisted grinding | Berberine chloride | Citric acid [ |
| Ligustrazine | Ethinylestradiol [ | |
| Baicalein | Nicotinamide [ | |
| Celastrol | Threonine [ |
Note: * indicates belonging to non-GARS or non-drug compounds.
Physicochemical properties modified through pharmaceutical cocrystals.
| Pharmaceutical Applications | Drug | Coformer |
|---|---|---|
| Enhanced solubility and dissolution rate | Andrographolide | Salicylic acid [ |
| 11-Aza-artemisinin | Benzoic acid [ | |
| Baicalein | Isoniazid [ | |
| Berberine chloride | Fumaric acid [ | |
| Celastrol | Threonine [ | |
| Curcumin | Resorcinol [ | |
| Ligustrazine | Saccharine [ | |
| Myricetin | Berberine chloride [ | |
| Oleanolic acid | Ethylenediamine [ | |
| Puerarin | Lornoxicam [ | |
| Quercetin | Isonicotinamide [ | |
| Ursolic acid | Piperazine [ | |
| Hygroscopicity | Baicalein | Isoniazid [ |
| Berberine | Chrysin [ | |
| Berberine chloride | Saccharin [ | |
| Curcumin | Resorcinol [ | |
| Dihydromyricetin | Berberine chloride [ | |
| Ferulic acid | Isonicotinamide [ | |
| Myricetin | Berberine chloride [ | |
| Oleanolic acid | Ethylenediamine [ | |
| Quercetin | Betaine [ | |
| Ursolic acid | Piperazine [ | |
| Extended release | Curcumin | Isoniazid [ |
| Piperazine ferulate | Pyrazinamide [ | |
| Improved tabletability | Baicalein | Nicotinamide [ |
| Berberine chloride | Saccharine [ | |
| Puerarin | Lornoxicam [ | |
| Improved thermal stability | Berberine chloride | Fumaric acid [ |
| Ligustrazine | Saccharin [ | |
| Taste masking | Berberine chloride | Saccharin [ |
| Ligustrazine | saccharine [ | |
| Increased Chemical stability | Andrographolide | Salicylic acid [ |
Note: * indicates belonging to non-GARS or non-drug compounds.
Figure 7(a) Dissolution profiles of INH from different samples in pH 1.2 buffer solution (n = 3); (b) dissolution profile of INH from 2:1 INH-CUR cocrystal in the presence of RIF in pH 1.2 and pH 6.8 buffer solutions (n = 3) [90] (with permission from [90]; Copyright 2020 American Chemical Society).
Figure 8Tabletability of (a) BAI-NCT, (b) BAI-CAF, and (c) BAI-ISN cocrystal systems (n = 3). Some error bars are hidden by symbols. The dashed lines correspond to 2 MPa tensile strength [69] (Reproduced from ref. [69] with permission from the Royal Society of Chemistry).
Figure 9(a) Crystal packing diagram (hydrogen bonds are shown as blue lines) and (b) energy framework of BAI α form viewed into c axis (radius of each cylinder represents the relative strength of interaction). The threshold interaction energy is set at −5 kJ mol−1 [69] (Reproduced from ref. [69] with permission from the Royal Society of Chemistry).
Figure 10Energy framework of BAI–CAF viewed along (a) b axis and (b) c axis. The layers are boxed. The threshold interaction energy is set at −20 kJ mol−1 [69] (Reproduced from ref. [69] with permission from the Royal Society of Chemistry).
Figure 11A two-dimensional classical hydrogen bonding network, in which an aromatic stacking interaction is observed between the benzene ring of FLA and the near pyrazine ring of PRA. Symmetry codes: (i) 2—x, 3—y, 1—z; (ii) –x—1, -y, -z; (iii) x + 1, y, z; (iv) x—1, y, z [134] (with permission from [134]; Copyright 2020 American Chemical Society).
Figure 12Crystal packing of FA-INA cocrystal showing hydrogen-bonded sheet structure mediated by acid–acid and amide–amide homosynthons and hydroxyl-pyridine heterosynthon [100] (With permission from [100]; Copyright 2020 Elsevier).
Figure 13The crystal structures of BCl–CA cocrystal: (a) thermal ellipsoid drawing including atomic labelling scheme, (b) key intermolecular interactions (hydrogen bonds are teal colored), (c) molecular packing [60] (with permission from [60]; Copyright 2019 Elsevier).
Figure 14Crystal structure of QUE-BTN. (a) The asymmetric unit. (b) Two asymmetric units formed R44 (24) dimeric structure. (c) 2D layered structure in the ac plane. Each dimeric structure in c is displayed in a different color. (d) 3D packing structure viewed along the c axis. In (d), adjacent molecular layers are displayed in different colors [71] (with permission from [71]; Copyright 2019 American Chemical Society).